Pulmonary delivery is becoming an increasingly attractive route for biologic therapies, offering rapid absorption, avoidance of first-pass metabolism, and the potential for needle-free self-administration. However, developing inhalable biologics presents significant formulation and manufacturing challenges. Maintaining molecular stability while engineering particles capable of reaching the deep lung requires a highly specialised approach.
In this whitepaper, Dr Richard Johnson, Chief Scientific Officer at Upperton, explores how spray drying has emerged as a leading technology for producing inhalable dry powder biologics. Learn how formulation science, excipient selection, particle engineering, aerodynamic performance testing, and stability assessment combine to support the successful development of pulmonary dosage forms.
Key Takeaways
Download this whitepaper to learn:
- Why pulmonary delivery is attracting growing interest for biologics and complex therapeutic molecules.
- How spray drying creates inhalable dry powders with precise particle size and aerodynamic characteristics.
- The role of particle engineering in achieving effective lung deposition and clinical performance.
- How excipients help preserve biologic stability, potency, and activity during spray drying.
- The formulation approaches used for peptides, monoclonal antibodies, vaccines, and other biologics.
- How delivery performance is measured through fine particle fraction testing and aerodynamic characterisation.
- Key considerations for storage stability and successful dry powder inhaler (DPI) development.